Latest market price
4.55
-1.86-28.94%
OverviewShort InterestFilings
GYREQT26Gyre Therapeutics, Inc.·NASDAQ
4.55-28.94%
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-0.20Insider Own—Shs Outstand106.03MPerf Week-22.05%
Market Cap483.52MForward P/E—EPS next Y-0.23Insider Trans-0.18%Shs Float31.25MPerf Month-34.86%
Enterprise Value410.52MPEG—EPS next Q-0.15Short Float6.17%Perf Quarter-25.37%
Income-18.00MP/S4.03EPS this Y-344.90%Short Ratio17.51Perf Half Y-41.54%
Sales120.00MP/B2.93EPS next Y—ROA-8.70%Short Interest1.93MPerf YTD-35.41%
Book/sh1.56P/C6.45EPS next 5Y—ROE-15.77%52W High9.13 -50.11%Perf Year-39.52%
Cash/sh0.71P/FCF—EPS past 3/5Y-9.14% —ROIC-9.69%52W Low4.50 1.11%Perf 3Y-42.64%
Dividend Est.—EV/EBITDA—Sales past 3/5Y4.68% 40.99%Gross Margin94.30%Volatility12.60% 6.15%Perf 5Y-91.24%
Dividend TTM—EV/Sales3.42EPS Y/Y TTM—Oper. Margin-13.97%ATR (14)0.48Perf 10Y-97.80%
Dividend Ex-DateJan 13, 2023Quick Ratio3.86Sales Y/Y TTM14.29%Profit Margin-14.52%RSI (14)29.53Recom2.00
Dividend Gr. 3/5Y—Current Ratio4.26EPS Q/Q—SMA20-28.93%Beta2.57Target Price17.00
Payout0.00%Debt/Eq0.01Sales Q/Q-3.33%SMA50-32.27%Rel Volume3.03Prev Close6.41
Employees625LT Debt/Eq0.01EarningsNov 06SMA200-34.75%Avg Volume129.83KPrice4.55
IPO DateApr 12, 2006Option/ShortYes / YesEPS/Sales Surpr.-111.76% 9.87%Net Debt/EBITDA—Volume393,771Change-28.94%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-10-25InitiatedJefferiesBuy$16
Aug-26-25InitiatedH.CBuy$18
Latest News· Times ET
Oct-29-26
Oct-29-2607:35AM
Incyte (INCY) Reports Q3 Loss, Beats Revenue EstimatesYahoo
Oct-22-26
Oct-22-2612:33PM
Gyre Therapeutics Signs Employment Agreement For Ying To Continue As CEO, Thomas Eastling As CFOBenzinga
Sep-29-26
Sep-29-2606:15AM
Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)defenseworld.net
Sep-03-26
Sep-03-2607:00AM
Gyre Therapeutics to Participate in Upcoming September Investor Conferencesglobenewswire.com
Aug-07-26
Aug-07-2609:20AM
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimateszacks.com
07:00AM
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Updateglobenewswire.com
04:00AM
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M EstBenzinga
Jul-16-26
Jul-16-2604:05PM
Gyre Therapeutics Appoints Three New Members to its Board of Directorsglobenewswire.com
Company

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue120117106113—————
Cost of Goods Sold Incl. D&A7545—————
Gross Profit112111102109—————
Selling, General and Administrative Excl. Other94867476—————
Research and Development33141214—————
Other Operating Expense20086—————
Operating Income-161116-67—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)137-10—————
Net Income Before Taxes-151423-77—————
Income Taxes2559—————
Consolidated Net Income-18512-93—————
Net Income From Continuing Operations-181018-85—————
Net Income-18512-93—————
EPS (Recurring)-0.200.060.14-1.41—————
EPS (Basic, Before Extraordinaries)-0.200.060.14-1.41—————
EPS (Diluted)-0.200.020.05-1.41—————
EBITDA-13171820—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—313.78242.00——————
Price To Sales Ratio3.835.379.7015.00—————
Gross Margin93.3394.8796.2396.46—————
Operating Margin-13.339.4015.09-59.29—————
Net Margin-15.004.2711.32-82.30—————
Shares Outstanding101898566—————
Market Capitalization4606281,0291,696—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$9.52$8.12$6.71$5.31$3.91● Close Price0.00K115.41K230.82K346.23K461.64KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ye WeiguoChief Operating OfficerJun 18 '26Sale6.353,00019,050700,000Jun 22
Ye WeiguoChief Operating OfficerJun 18 '26Option Exercise0.753,0002,250703,000Jun 22
Ye WeiguoChief Operating OfficerJun 10 '26Option Exercise0.7511,4188,564706,418Jun 22
Ye WeiguoChief Operating OfficerJun 10 '26Sale6.2211,41871,056700,000Jun 22
Ye WeiguoChief Operating OfficerJun 09 '26Sale6.1417,500107,480700,000Jun 22
Ye WeiguoChief Operating OfficerJun 09 '26Option Exercise0.7517,50013,125835,701Jun 22
Ye WeiguoChief Operating OfficerJun 11 '26Option Exercise0.752,8002,100702,800Jun 15
Ye WeiguoChief Operating OfficerJun 11 '26Sale6.172,80017,276700,000Jun 15
Ye WeiguoChief Operating OfficerJun 05 '26Option Exercise0.7515,40111,551715,401Jun 08
Ye WeiguoChief Operating OfficerJun 05 '26Sale6.4015,40198,566700,000Jun 08
Ye WeiguoChief Operating OfficerJun 04 '26Option Exercise0.7519,57514,681719,575Jun 08
Ye WeiguoChief Operating OfficerJun 04 '26Sale6.1319,575119,995700,000Jun 08
Ye WeiguoChief Operating OfficerMay 26 '26Option Exercise0.754,0003,000704,000May 27
Ye WeiguoChief Operating OfficerMay 26 '26Sale6.104,00024,400700,000May 27
Ye WeiguoChief Operating OfficerMay 22 '26Option Exercise0.753,5002,625703,500May 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.